Elanix Biotechnologies AG

  • WKN: A0WMJQ
  • ISIN: DE000A0WMJQ4
  • Land: Deutschland

Nachricht vom 14.02.2019 | 09:21

Elanix Biotechnologies AG: Resignation in Supervisory Board

Elanix Biotechnologies AG / Key word(s): Personnel
Elanix Biotechnologies AG: Resignation in Supervisory Board

14-Feb-2019 / 09:21 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Elanix Biotechnologies AG: Resignation in Supervisory Board

Berlin, February 14, 2019 - Today, the chairman of the supervisory board of Elanix Biotechnologies AG ("Company", "Elanix"), Mr. Jürgen Kullmann, has notified the CEO that he will resign from office with immediate effect for health reasons and retire from the Supervisory Board.

The Management Board would like to thank Mr. Kullmann for his work on the Supervisory Board of the Company and will ask to the Local Court of Berlin to appoint a successor.

Lee Ann Laurent-Applegate
CEO

Contacts

Elanix Biotechnologies AG
Lee Ann Laurent-Applegate
Tel: +41 (0)22 363 66 40
investor.relations@elanix-bt.com

About Elanix

Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing.
Forward-looking statements

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


14-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

News im Fokus

Merck KGaA: Merck KGaA löst Rückstellung für Rechtsstreit in Höhe von EUR 365 Millionen auf

29. September 2020, 18:06

Aktuelle Research-Studie

Schloss Wachenheim AG

Original-Research: Schloss Wachenheim AG (von First Berlin Equity Research GmbH): Kaufen

29. September 2020